mk2 Biotechnologies, a peptide and protein production specialist for large-scale applications, and Sartorius Stedim Biotech Corporate Research, a leading technology and solutions provider to the biotech/biopharma industry, are happy to announce that they are joining forces to create the next-generation, low-cost biologics production platform. Integrating an intensified approach, the platform...

Joint Press Release mk2 Biotechnologies, WACKER and TUM mk2 Biotechnologies, WACKER and the Technical University of Munich (TUM) today announced their joint project targeting the development, large-scale production and purification of antimicrobial peptides (AMPs) for diverse applications. The project will run for two years. The aim is to take the...

Munich-based mk2 Biotechnologies today announced the receipt of several million Euros in seed funding to accelerate the further growth of the company. In particular, the company thrives to accomplish additional development milestones towards industrializing its novel peptide production platform. The financing round was led by OCCIDENT, with significant funds also...